Publications
NIBIOs employees contribute to several hundred scientific articles and research reports every year. You can browse or search in our collection which contains references and links to these publications as well as other research and dissemination activities. The collection is continously updated with new and historical material.
2018
Abstract
No abstract has been registered
Abstract
No abstract has been registered
Abstract
http://www.sterf.org/Media/Get/2978/annual-report-2017
Abstract
No abstract has been registered
Authors
Tatsiana EspevigAbstract
No abstract has been registered
Authors
Tatsiana EspevigAbstract
No abstract has been registered
Abstract
No abstract has been registered
Authors
Sjur Spildo PrestegardAbstract
No abstract has been registered
Abstract
No abstract has been registered
Authors
Mihaela-Olivia Dobrica Catalin Lazar Lisa Paruch Andre van Eerde Jihong Liu Clarke Catalin Tucureanu Iuliana Caras Sonya Ciulean Adrian Onu Vlad Tofan Alexandru Branzan Stephan Urban Crina Stavaru Norica Branza-NichitaAbstract
Hepatitis B Virus (HBV) infection can be prevented by vaccination. Vaccines containing the small (S)envelope protein are currently used in universal vaccination programs and achieve protective immuneresponse in more than 90% of recipients. However, new vaccination strategies are necessary for successfulimmunization of the remaining non- or low-responders. We have previously characterized a novel HBVchimeric antigen, which combines neutralization epitopes of the S and the preS1 domain of the large (L)envelope protein (genotype D). The S/preS121–47chimera produced in mammalian cells and Nicotianabenthamiana plants, induced a significantly stronger immune response in parenterally vaccinated micethan the S protein. Here we describe the transient expression of the S/preS121–47antigen in an edibleplant, Lactuca sativa, for potential development of an oral HBV vaccine. Our study shows that oral admin-istration of adjuvant-free Lactuca sativa expressing the S/preS121–47antigen, three times, at 1lg/dose,was sufficient to trigger a humoral immune response in mice. Importantly, the elicited antibodies wereable to neutralize HBV infection in an NTCP-expressing infection system (HepG2-NTCP cell line) moreefficiently than those induced by mice fed on Lactuca sativa expressing the S protein. These results sup-port the S/preS121–47antigen as a promising candidate for future development as an edible HBV vaccine.